PCL Inc
PCL, Inc. provides multiplex in vitro diagnostic (IVD) products and platform services. The company offers HiSU solution, an automated multi-immune diagnostic system that performs various diagnostics, high-speed tests including blood screening, multiple cancer screening, autoimmune testing, etc. It also provides antigen and antibody diagnostic kits, including PCLOK II anti-HIV/HCV/syphilis, and PC… Read more
Market Cap & Net Worth: PCL Inc (241820)
PCL Inc (KQ:241820) has a market capitalization of $12.20 Million (₩17.87 Billion) as of March 19, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #29162 globally and #1965 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PCL Inc's stock price ₩302.00 by its total outstanding shares 59172000 (59.17 Million).
PCL Inc Market Cap History: 2017 to 2025
PCL Inc's market capitalization history from 2017 to 2025. Data shows change from $208.48 Million to $12.20 Million (-23.84% CAGR).
Index Memberships
PCL Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$167.61 Billion | 0.01% | #1082 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$167.61 Billion | 0.01% | #1082 of 1384 |
Weight: PCL Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
PCL Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PCL Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.02x
PCL Inc's market cap is 0.02 times its annual revenue
0.67x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $208.48 Million | $506.14 Million | -$3.87 Billion | 0.41x | N/A |
| 2018 | $115.35 Million | $128.54 Million | -$5.77 Billion | 0.90x | N/A |
| 2019 | $96.85 Million | $35.81 Million | -$7.97 Billion | 2.70x | N/A |
| 2020 | $439.18 Million | $53.68 Billion | $19.51 Billion | 0.01x | 0.02x |
| 2021 | $427.17 Million | $46.15 Billion | -$31.67 Billion | 0.01x | N/A |
| 2022 | $179.64 Million | $37.22 Billion | -$4.02 Billion | 0.00x | N/A |
| 2023 | $144.88 Million | $8.43 Billion | -$20.32 Billion | 0.02x | N/A |
| 2024 | $22.39 Million | $1.25 Billion | -$52.34 Billion | 0.02x | N/A |
Competitor Companies of 241820 by Market Capitalization
Companies near PCL Inc in the global market cap rankings as of March 19, 2026.
Key companies related to PCL Inc by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #84 globally with a market cap of $187.53 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #151 globally with a market cap of $119.88 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #170 globally with a market cap of $111.60 Billion USD.
- Boston Scientific Corp (NYSE:BSX): Ranked #183 globally with a market cap of $105.38 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #84 | Abbott Laboratories | NYSE:ABT | $187.53 Billion | $108.49 |
| #151 | Stryker Corporation | NYSE:SYK | $119.88 Billion | $345.81 |
| #170 | Medtronic PLC | NYSE:MDT | $111.60 Billion | $87.21 |
| #183 | Boston Scientific Corp | NYSE:BSX | $105.38 Billion | $71.28 |
PCL Inc Historical Marketcap From 2017 to 2025
Between 2017 and today, PCL Inc's market cap moved from $208.48 Million to $ 12.20 Million, with a yearly change of -23.84%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | ₩12.20 Million | -45.49% |
| 2024 | ₩22.39 Million | -84.55% |
| 2023 | ₩144.88 Million | -19.35% |
| 2022 | ₩179.64 Million | -57.95% |
| 2021 | ₩427.17 Million | -2.74% |
| 2020 | ₩439.18 Million | +353.47% |
| 2019 | ₩96.85 Million | -16.04% |
| 2018 | ₩115.35 Million | -44.67% |
| 2017 | ₩208.48 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of PCL Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $12.20 Million USD |
| MoneyControl | $12.20 Million USD |
| MarketWatch | $12.20 Million USD |
| marketcap.company | $12.20 Million USD |
| Reuters | $12.20 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.